{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:56:12Z","timestamp":1793382972265,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-12849-y","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T16:44:30Z","timestamp":1771346670000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating B\/F\/TAF at the first HIV-specialist appointment in antiretroviral naive persons living with HIV: the bifast study"],"prefix":"10.1186","volume":"26","author":[{"given":"Aws Waleed","family":"Al-Hayani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Carrillo-Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Cabello-\u00dabeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Algar-Arevalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Prieto-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"\u00c1lvarez-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"T\u00e9llez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel Luis","family":"Casta\u00f1o-N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Sanchez-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Fuensalida-Novo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macarena","family":"Bonilla-Porras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Burillo-Cubillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mu\u00f1oz-Ugarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Verano-Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"G\u00f3rgolas-Hern\u00e1ndez-Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"12849_CR1","unstructured":"UNAIDS, Global HIV. & AIDS statistics \u2014 Fact sheet 2024 [Internet]. 2024 [cited 2024 Dec 2]. https:\/\/www.unaids.org\/en\/resources\/fact-sheet. Accessed 2 Dec 2024."},{"key":"12849_CR2","unstructured":"ECDC. HIV\/AIDS Surveillance in Europe. 2024\u20132023 data [Internet]. 2024 [cited 2024 Dec 2]. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/hiv-aids-surveillance-europe-2024-2023-data. Accessed 2 Dec 2024."},{"key":"12849_CR3","unstructured":"World Health Organization (WHO). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach [Internet]. 2021 [cited 2022 Dec 19]. https:\/\/www.who.int\/publications\/i\/item\/9789240031593. Accessed 19 Dec 2022."},{"key":"12849_CR4","doi-asserted-by":"publisher","unstructured":"Pilcher CD, Ospina-Norvell C, Dasgupta A, Jones D, Hartogensis W, Torres S et al. The effect of Same-Day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a US public health Setting. J acquir immune defic syndr [Internet]. J Acquir Immune Defic Syndr; 2017 [cited 2022 Jan 25];74:44\u201351. https:\/\/doi.org\/10.1097\/QAI.0000000000001134","DOI":"10.1097\/QAI.0000000000001134"},{"key":"12849_CR5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa1105243","volume":"365","author":"MS Cohen","year":"2011","unstructured":"Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa1105243.","journal-title":"N Engl J Med"},{"key":"12849_CR6","doi-asserted-by":"publisher","first-page":"e0236032","DOI":"10.1371\/journal.pone.0236032","volume":"15","author":"J Berenguer","year":"2020","unstructured":"Berenguer J, Parrondo J, Landovitz RJ. Quantifying the reduction in sexual transmission of HIV-1 among MSM by early initiation of ART: A mathematical model. PLoS ONE. 2020;15:e0236032. https:\/\/doi.org\/10.1371\/journal.pone.0236032.","journal-title":"PLoS ONE"},{"key":"12849_CR7","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1016\/S0140-6736(19)30418-0","volume":"393","author":"AJ Rodger","year":"2019","unstructured":"Rodger AJ, Cambiano V, Phillips AN, Bruun T, Raben D, Lundgren J, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet [Internet] Lancet. 2019;393:2428\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(19)30418-0. [cited 2022 May 1];.","journal-title":"Lancet [Internet] Lancet"},{"key":"12849_CR8","doi-asserted-by":"publisher","unstructured":"Bavinton BR, Pinto AN, Phanuphak N, Grinsztejn B, Prestage GP, Zablotska-Manos IB, Lancet HIV et al. 2018 [cited 2022 Jan 25];5:e438\u201347. https:\/\/doi.org\/10.1016\/S2352-3018(18)30132-2","DOI":"10.1016\/S2352-3018(18)30132-2"},{"key":"12849_CR9","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1506816","volume":"373","author":"JD Lundgren","year":"2015","unstructured":"Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1506816.","journal-title":"N Engl J Med"},{"key":"12849_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/QAD.0000000000001671","volume":"32","author":"N Ford","year":"2018","unstructured":"Ford N, Migone C, Calmy A, Kerschberger B, Kanters S, Nsanzimana S, et al. Benefits and risks of rapid initiation of antiretroviral therapy. AIDS. 2018;32:17\u201323. https:\/\/doi.org\/10.1097\/QAD.0000000000001671.","journal-title":"AIDS"},{"key":"12849_CR11","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDOA2200302","author":"Group INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study","year":"2023","unstructured":"Group INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study. Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection. NEJM Evidence [Internet]. Massachusetts Medical Society; 2023 [cited 2023 Nov 13];2. https:\/\/doi.org\/10.1056\/EVIDOA2200302."},{"key":"12849_CR12","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1056\/NEJMoa1110187","volume":"368","author":"T Le","year":"2013","unstructured":"Le T, Wright EJ, Smith DM, He W, Catano G, Okulicz JF, et al. Enhanced CD4\u2009+\u2009T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med United States. 2013;368:218\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1110187.","journal-title":"N Engl J Med United States"},{"key":"12849_CR13","doi-asserted-by":"publisher","unstructured":"Ugarte A, Mora LD, La L, Chivite I, Fern\u00e1ndez E, Inciarte A et al. Rapid initiation of bictegravir\/emtricitabine\/tenofovir alafenamide as first-line therapy in HIV infection. A prospective study. Journal of Antimicrobial Chemotherapy [Internet]. Oxford Academic; 2024 [cited 2024 Dec 2];79:2343\u201353. https:\/\/doi.org\/10.1093\/JAC\/DKAE235","DOI":"10.1093\/JAC\/DKAE235"},{"key":"12849_CR14","doi-asserted-by":"publisher","unstructured":"Chen IW, Sun HY, Hung CC. Meta-Analysis of efficacy and safety of coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide among people living with HIV. Infect Dis Ther [Internet]. Adis; 2021 [cited 2024 Dec 2];10:1331\u201346. https:\/\/doi.org\/10.1007\/S40121-021-00449-Z\/FIGURES\/3","DOI":"10.1007\/S40121-021-00449-Z\/FIGURES\/3"},{"key":"12849_CR15","unstructured":"EACS European AIDS Clinical Society EACS Guidelines 12.0. 2023 [cited 2024 Jul 8]; https:\/\/www.eacsociety.org\/media\/guidelines-12.0.pdf. Accessed 8 Jul 2024."},{"key":"12849_CR16","unstructured":"Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV. [cited 2024 Dec 2]; https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv. Accessed 2 Dec 2024."},{"key":"12849_CR17","unstructured":"Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. 2023 [cited 2023 Jul 19]; https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv. Accessed 19 Jul 2023."},{"key":"12849_CR18","unstructured":"European AIDS, October Clinical Society. EACS Guidelines version 11.1, 2022. 2022 [cited 2023 Jul 19]; https:\/\/www.eacsociety.org\/media\/guidelines-11.1_final_09-10.pdf. Accessed 19 Jul 2023."},{"key":"12849_CR19","unstructured":"Panel de expertos de GeSIDA y Plan Nacional sobre el Sida. Documento de consenso de GeSIDA\/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana. 2023."},{"key":"12849_CR20","unstructured":"World Health Organization (WHO). Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach. World Health Organization. 2021 [cited 2023 Jun 30]; https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572729\/. Accessed 30 Jun 2023."},{"key":"12849_CR21","doi-asserted-by":"publisher","unstructured":"Eshun-Wilson I, Okwen MP, Richardson M, Bicanic T. Early versus delayed antiretroviral treatment in HIV-positive people with Cryptococcal meningitis. Cochrane database syst rev [Internet]. Cochrane Database Syst Rev; 2018 [cited 2023 Jul 27];7. https:\/\/doi.org\/10.1002\/14651858.CD009012.PUB3","DOI":"10.1002\/14651858.CD009012.PUB3"},{"issue":"Suppl 1","key":"12849_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/hiv.12708","volume":"20","author":"MA Boyd","year":"2019","unstructured":"Boyd MA, Boffito M, Castagna A, Estrada V. Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps. HIV Med Engl. 2019;20(Suppl 1):3\u201311. https:\/\/doi.org\/10.1111\/hiv.12708.","journal-title":"HIV Med Engl"},{"key":"12849_CR23","doi-asserted-by":"publisher","first-page":"e1002015","DOI":"10.1371\/JOURNAL.PMED.1002015","volume":"13","author":"S Rosen","year":"2016","unstructured":"Rosen S, Maskew M, Fox MP, Nyoni C, Mongwenyana C, Malete G, et al. Initiating antiretroviral therapy for HIV at a patient\u2019s first clinic visit: the RapIT randomized controlled trial. PLoS Med [Internet] Public Libr Sci. 2016;13:e1002015. https:\/\/doi.org\/10.1371\/JOURNAL.PMED.1002015. [cited 2022 Jan 25];.","journal-title":"PLoS Med [Internet] Public Libr Sci"},{"key":"12849_CR24","doi-asserted-by":"publisher","unstructured":"Huhn GD, Crofoot G, Ramgopal M, Gathe J, Bolan R, Luo D et al. Darunavir\/Cobicistat\/Emtricitabine\/Tenofovir Alafenamide in a Rapid-Initiation model of care for human immunodeficiency virus type 1 infection: primary analysis of the DIAMOND Study. Clin infect dis [Internet]. Clin Infect Dis; 2020 [cited 2022 Jan 25];71:3110\u20137. https:\/\/doi.org\/10.1093\/CID\/CIZ1213","DOI":"10.1093\/CID\/CIZ1213"},{"key":"12849_CR25","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/JAC\/DKAD008","volume":"78","author":"A Bachelard","year":"2023","unstructured":"Bachelard A, Isernia V, Charpentier C, Benalycherif A, Mora M, Donadille C, et al. Same-day initiation of bictegravir\/emtricitabine\/tenofovir alafenamide: week 48 results of the FAST study-IMEA 055. J Antimicrob Chemother [Internet] J Antimicrob Chemother. 2023;78:769\u201378. https:\/\/doi.org\/10.1093\/JAC\/DKAD008. [cited 2023 Nov 13];.","journal-title":"J Antimicrob Chemother [Internet] J Antimicrob Chemother"},{"key":"12849_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/OFID\/OFAD101","author":"CP Rolle","year":"2023","unstructured":"Rolle CP, Berhe M, Singh T, Ortiz R, Wurapa A, Ramgopal M et al. Sustained Virologic Suppression With Dolutegravir\/Lamivudine in a Test-and-Treat Setting Through 48 Weeks. Open Forum Infect Dis [Internet]. Open Forum Infect Dis; 2023 [cited 2023 Nov 13];10. https:\/\/doi.org\/10.1093\/OFID\/OFAD101."},{"key":"12849_CR27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/QAD.0000000000004046","volume":"39","author":"KNC Duong","year":"2025","unstructured":"Duong KNC, Schmutz HW, Ben-Umeh KC, Duru EE, Rose N, Trom C, et al. Real-world clinical and economic outcomes from rapid start antiretroviral therapy in HIV: systematic review and meta-analysis. AIDS [Internet] AIDS. 2025;39:241\u201352. https:\/\/doi.org\/10.1097\/QAD.0000000000004046. [cited 2025 Oct 23];.","journal-title":"AIDS [Internet] AIDS"},{"key":"12849_CR28","doi-asserted-by":"publisher","unstructured":"Amanyire G, Semitala FC, Namusobya J, Katuramu R, Kampiire L, Wallenta J, Lancet HIV et al. 2016 [cited 2022 Jan 25];3:e539\u201348. https:\/\/doi.org\/10.1016\/S2352-3018(16)30090-X","DOI":"10.1016\/S2352-3018(16)30090-X"},{"key":"12849_CR29","doi-asserted-by":"publisher","unstructured":"Koenig SP, Dorvil N, D\u00e9vieux JG, Hedt-Gauthier BL, Riviere C, Faustin M et al. Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trial. PLoS med [Internet]. PLoS Med; 2017 [cited 2022 Jan 25];14. https:\/\/doi.org\/10.1371\/JOURNAL.PMED.1002357","DOI":"10.1371\/JOURNAL.PMED.1002357"},{"key":"12849_CR30","doi-asserted-by":"publisher","unstructured":"Labhardt ND, Ringera I, Lejone TI, Klimkait T, Muhairwe J, Amstutz A et al. Effect of offering Same-Day ART vs usual health facility referral during Home-Based HIV testing on linkage to care and viral suppression among adults with HIV in lesotho: the CASCADE randomized clinical Trial. JAMA [Internet]. JAMA; 2018 [cited 2022 Jan 25];319:1103\u201312. https:\/\/doi.org\/10.1001\/JAMA.2018.1818","DOI":"10.1001\/JAMA.2018.1818"},{"key":"12849_CR31","doi-asserted-by":"publisher","unstructured":"Huang YC, Sun HY, Chuang YC, Huang YS, Lin KY, Huang SH et al. Short-term outcomes of rapid initiation of antiretroviral therapy among HIV-positive patients: real-world experience from a single-centre retrospective cohort in Taiwan. BMJ open [Internet]. BMJ Open; 2019 [cited 2025 Oct 24];9. https:\/\/doi.org\/10.1136\/BMJOPEN-2019-033246","DOI":"10.1136\/BMJOPEN-2019-033246"},{"key":"12849_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0227572","author":"RR Lilian","year":"2020","unstructured":"Lilian RR, Rees K, McIntyre JA, Struthers HE, Peters RPH. Same-day antiretroviral therapy initiation for HIV-infected adults in South africa: analysis of routine data. PLoS One [Internet] PLoS One. 2020. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0227572. [cited 2025 Oct 24];15.","journal-title":"PLoS One [Internet] PLoS One"},{"key":"12849_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/JIA2.25529","author":"D Joseph Davey","year":"2020","unstructured":"Joseph Davey D, Kehoe K, Serrao C, Prins M, Mkhize N, Hlophe K, et al. Same-day antiretroviral therapy is associated with increased loss to follow-up in South African public health facilities: a prospective cohort study of patients diagnosed with HIV. J Int AIDS Soc [Internet] J Int AIDS Soc. 2020. https:\/\/doi.org\/10.1002\/JIA2.25529. [cited 2025 Oct 24];23.","journal-title":"J Int AIDS Soc [Internet] J Int AIDS Soc"},{"key":"12849_CR34","doi-asserted-by":"publisher","unstructured":"Sax PE, Arribas JR, Orkin C, Lazzarin A, Pozniak A, DeJesus E et al. Bictegravir\/emtricitabine\/tenofovir Alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials. EClinicalMedicine [Internet]. EClinicalMedicine; 2023 [cited 2023 Nov 13];59. https:\/\/doi.org\/10.1016\/J.ECLINM.2023.101991","DOI":"10.1016\/J.ECLINM.2023.101991"},{"key":"12849_CR35","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/JAC\/DKAB481","volume":"77","author":"J Ambrosioni","year":"2022","unstructured":"Ambrosioni J, Rojas Li\u00e9vano J, Berrocal L, Inciarte A, De La Mora L, Gonz\u00e1lez-Cord\u00f3n A, et al. Real-life experience with bictegravir\/emtricitabine\/tenofovir Alafenamide in a large reference clinical centre. J Antimicrob Chemother [Internet] J Antimicrob Chemother. 2022;77:1133\u20139. https:\/\/doi.org\/10.1093\/JAC\/DKAB481. [cited 2023 Nov 13];.","journal-title":"J Antimicrob Chemother [Internet] J Antimicrob Chemother"},{"key":"12849_CR36","unstructured":"Integrase Inhibitor Versus Protease Inhibitor Based Therapy for People with Advanced HIV Disease (LAPTOP). CROI 2025, San Francisco, CA (March 9\u201312, 2025) [Internet]. 2025 [cited 2025 Oct 23]. https:\/\/www.natap.org\/2025\/CROI\/croi_218.htm. Accessed 23 Oct 2025."},{"key":"12849_CR37","doi-asserted-by":"publisher","unstructured":"Croxford S, Burns F, Copas A, Pharris A, Rinder Stengaard A, Delpech V. Factors associated with delayed linkage to care following HIV diagnosis in the WHO European Region. HIV med [Internet]. HIV Med; 2018 [cited 2023 Nov 13];19 Suppl 1:40\u20136. https:\/\/doi.org\/10.1111\/HIV.12585","DOI":"10.1111\/HIV.12585"},{"key":"12849_CR38","doi-asserted-by":"publisher","unstructured":"Koester KA, Moran L, LeTourneau N, VanderZanden L, Coffey S, Crouch PC et al. Essential elements of and challenges to rapid ART implementation: a qualitative study of three programs in the united States. BMC infect dis [Internet]. BMC Infect Dis; 2022 [cited 2023 Nov 13];22. https:\/\/doi.org\/10.1186\/S12879-022-07297-3","DOI":"10.1186\/S12879-022-07297-3"},{"key":"12849_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/OFID\/OFAD292","author":"DAE White","year":"2023","unstructured":"White DAE, Jewett M, Burns M, Godoy A, Basham K, Makinde O et al. Implementing a Rapid Antiretroviral Therapy Program Using Starter Packs for Emergency Department Patients Diagnosed With HIV Infection. Open Forum Infect Dis [Internet]. Open Forum Infect Dis; 2023 [cited 2025 Oct 23];10. https:\/\/doi.org\/10.1093\/OFID\/OFAD292."},{"key":"12849_CR40","doi-asserted-by":"publisher","DOI":"10.1093\/OFID\/OFAD531","author":"A Dalal","year":"2023","unstructured":"Dalal A, Clark E, Samiezade-Yazd Z, Lee-Rodriguez C, Lam JO, Luu MN. Outcomes and Predictors of Rapid Antiretroviral Therapy Initiation for People With Newly Diagnosed HIV in an Integrated Health Care System. Open Forum Infect Dis [Internet]. Open Forum Infect Dis; 2023 [cited 2025 Oct 23];10. https:\/\/doi.org\/10.1093\/OFID\/OFAD531."},{"key":"12849_CR41","doi-asserted-by":"publisher","unstructured":"Gregori N, Renzetti S, Izzo I, Faletti G, Fumarola B, degli Antoni M et al. Does the rapid initiation of antiretroviral therapy at HIV diagnosis impact virological response in a real-life setting? A single-centre experience in Northern Italy. AIDS care [Internet]. AIDS Care; 2023 [cited 2025 Oct 23];35:1938\u201347. https:\/\/doi.org\/10.1080\/09540121.2023.2176425","DOI":"10.1080\/09540121.2023.2176425"},{"key":"12849_CR42","doi-asserted-by":"publisher","unstructured":"van Paassen P, Dijkstra M, Peay HL, Rokx C, Verbon A, Reiss P et al. Perceptions of rapid antiretroviral therapy initiation among participants of the Netherlands cohort study on acute HIV Infection. AIDS res Hum retroviruses [Internet]. AIDS Res Hum Retroviruses; 2024 [cited 2025 Oct 23];40:286\u201392. https:\/\/doi.org\/10.1089\/AID.2022.0169","DOI":"10.1089\/AID.2022.0169"},{"key":"12849_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/S10461-025-04658-2","author":"C Wells","year":"2025","unstructured":"Wells C, Driver R, Belanger D, Boos EM, Barkevich J, Tesoriero JM. Rapid Start of HIV Antiretroviral Therapy in New York State. AIDS Behav [Internet]. AIDS Behav; 2025 [cited 2025 Oct 23];29:1910\u20139. https:\/\/doi.org\/10.1007\/S10461-025-04658-2."},{"key":"12849_CR44","doi-asserted-by":"publisher","unstructured":"Hung CC, Phanuphak N, Wong CS, Olszyna DP, Kim TH. Same-day and rapid initiation of antiretroviral therapy in people living with HIV in Asia. How far have we come? HIV Med [Internet]. HIV Med; 2022 [cited 2025 Oct 23];23 Suppl 4:3\u201314. https:\/\/doi.org\/10.1111\/HIV.13410","DOI":"10.1111\/HIV.13410"},{"key":"12849_CR45","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1093\/JAC\/DKR291","volume":"66","author":"MA Wainberg","year":"2011","unstructured":"Wainberg MA, Moisi D, Oliveira M, Toni TDA, Brenner BG. Transmission dynamics of the M184V drug resistance mutation in primary HIV infection. J Antimicrob Chemother [Internet] J Antimicrob Chemother. 2011;66:2346\u20139. https:\/\/doi.org\/10.1093\/JAC\/DKR291. [cited 2025 Oct 24];.","journal-title":"J Antimicrob Chemother [Internet] J Antimicrob Chemother"},{"key":"12849_CR46","doi-asserted-by":"publisher","unstructured":"Sax PE, Andreatta K, Molina JM, Daar ES, Hagins D, Acosta R et al. High efficacy of switching to bictegravir\/emtricitabine\/tenofovir Alafenamide in people with suppressed HIV and preexisting M184V\/I. AIDS [Internet]. AIDS; 2022 [cited 2025 Oct 24];36:1511\u201320. https:\/\/doi.org\/10.1097\/QAD.0000000000003244","DOI":"10.1097\/QAD.0000000000003244"},{"key":"12849_CR47","doi-asserted-by":"publisher","unstructured":"Avihingsanon A, Lu H, Leong CL, Hung CC, Koenig E, Kiertiburanakul S, et al. Bictegravir, emtricitabine, and Tenofovir Alafenamide versus dolutegravir, emtricitabine, and Tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial. Lancet HIV [Internet]. Volume 10. Elsevier Ltd; 2023. pp. e640\u201352. [cited 2025 Oct 24];. https:\/\/doi.org\/10.1016\/S2352-3018(23)00151-0.","DOI":"10.1016\/S2352-3018(23)00151-0"},{"key":"12849_CR48","doi-asserted-by":"publisher","DOI":"10.1007\/S11908-021-00750-5","author":"SM Michienzi","year":"2021","unstructured":"Michienzi SM, Barrios M, Badowski ME. Evidence Regarding Rapid Initiation of Antiretroviral Therapy in Patients Living with HIV. Volume 23. Springer; 2021. p. 7. [cited 2025 Oct 24];. https:\/\/doi.org\/10.1007\/S11908-021-00750-5. Curr Infect Dis Rep [Internet]."},{"key":"12849_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/S12916-016-0640-4\/FIGURES\/3","author":"JV Lazarus","year":"2016","unstructured":"Lazarus JV, Safreed-Harmon K, Barton SE, Costagliola D, Dedes N, del Amo Valero J et al. Beyond viral suppression of HIV - the new quality of life frontier. BMC Med [Internet]. BioMed Central Ltd.; 2016 [cited 2023 Nov 13];14:1\u20135. https:\/\/doi.org\/10.1186\/S12916-016-0640-4\/FIGURES\/3."},{"key":"12849_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/S12955-017-0778-6","author":"V Cooper","year":"2017","unstructured":"Cooper V, Clatworthy J, Harding R, Whetham J, Brown A, Leon A, et al. Measuring quality of life among people living with HIV: a systematic review of reviews. Health Qual Life Outcomes [Internet] Health Qual Life Outcomes. 2017. https:\/\/doi.org\/10.1186\/S12955-017-0778-6. [cited 2023 Nov 13];15.","journal-title":"Health Qual Life Outcomes [Internet] Health Qual Life Outcomes"},{"key":"12849_CR51","doi-asserted-by":"publisher","unstructured":"Lifson AR, Grund B, Gardner EM, Kaplan R, Denning E, Engen N et al. Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infection. AIDS [Internet]. NIH Public Access; 2017 [cited 2023 Nov 13];31:953. https:\/\/doi.org\/10.1097\/QAD.0000000000001417","DOI":"10.1097\/QAD.0000000000001417"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12849-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12849-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12849-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T10:48:13Z","timestamp":1774435693000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12849-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12849"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12849-y","relation":{"references":[{"id-type":"doi","id":"10.1056\/EVIDOA2200302","asserted-by":"subject"},{"id-type":"doi","id":"10.1093\/OFID\/OFAD101","asserted-by":"subject"},{"id-type":"doi","id":"10.1093\/OFID\/OFAD292","asserted-by":"subject"},{"id-type":"doi","id":"10.1093\/OFID\/OFAD531","asserted-by":"subject"},{"id-type":"doi","id":"10.1007\/S10461-025-04658-2","asserted-by":"subject"},{"id-type":"doi","id":"10.1007\/S11908-021-00750-5","asserted-by":"subject"},{"id-type":"doi","id":"10.1186\/S12916-016-0640-4\/FIGURES\/3","asserted-by":"subject"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided informed consent for the study using a written consent form. The study was approved by the reference local ethics committee, Fundaci\u00f3n Jim\u00e9nez D\u00edaz Research Ethics Committee (C\u00f3mite de \u00c9tica de la Investigaci\u00f3n), reference number EC008-20_FJD. The research was conducted in accordance with General Data Protection Regulation (GDPR) and the Declaration of Helsinki on personal data protection. Trial Registration number EUDRACT: 2019-004871-38 (Sponsor`s Protocol Code: BIFAST; Sponsor Name: Fundacion Jimenez Diaz Health Research Institute; Registration Date: 2002-02-21; Start date: 2020-06-03). Complete tittle: Phase IV, single-center, open study to assess the benefits of the start of immediate treatment without immunovirological data (\u201cSame Day Treatment\u201d) compared to conventional treatment with BIC\/FTC\/TAF in naive patients with type 1 HIV infection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"627"}}